METAVIR vs Ishak Score 2026: F1-F4 Liver Fibrosis Staging
METAVIR (F0-F4) vs Ishak (0-6) liver fibrosis staging compared: origin, criteria, conversion table, and Kleiner/NASH CRN for MASH biopsy reads.
Why "F3" looks different from trial to trial
When drug developers read MASH, HCV, HBV, or PBC trial protocols, the first source of confusion is that terms like "F3," "stage 3," and "Ishak 4" shift meaning across trials, sites, and indications. The root cause: multiple histological scoring systems coexist, each with its own granularity and definitions.
This article reconciles the two dominant hepatic systems — METAVIR (F0-F4) and the Ishak score (0-6) — and connects them to the Kleiner/Brunt (NASH CRN) staging used in MASH trials, so preclinical and translational researchers can correctly interpret biopsy data.
Quick Answer: METAVIR is a 5-stage system (F0-F4) from Bedossa & Poynard 1996: F3 = bridging fibrosis, F4 = cirrhosis. Ishak is a 7-stage system (0-6) from Ishak 1995 that splits cirrhosis into "incomplete" (Ishak 5) and "established" (Ishak 6). Use METAVIR/Kleiner for regulatory Phase 2/3 primary endpoints; use Ishak for fibrosis regression and fine-grained cirrhosis characterization.
1. Quick reference of major scoring systems
| Score | Stages | Primary indication | Origin | Typical regulatory use |
|---|---|---|---|---|
| METAVIR | F0-F4 (5 stages) | HCV / HBV | Bedossa & Poynard 1996 PMID: 8690394 | FDA primary endpoint (≥1 stage improvement) |
| Ishak | 0-6 (7 stages) | HCV / HBV / AIH | Ishak K et al. 1995 PMID: 7560864 | Cirrhosis sub-staging, regression studies |
| Kleiner / Brunt (NASH CRN) | F0-F4 (F1 split into 1a/1b/1c) | MASH / NAFLD | Kleiner DE et al. 2005 PMID: 15915461 | MASH Phase 2/3 primary endpoint |
| Knodell HAI | 0-22 (composite) | HCV | Knodell 1981 PMID: 7308988 | Historical; largely superseded |
| Batts-Ludwig | 0-4 (5 stages) | Chronic hepatitis | Batts & Ludwig 1995 | Some North American centers |
Each score is a semi-quantitative architectural grade, not a measurement of collagen mass. Pair them with hydroxyproline assay or Sirius Red %CPA for absolute quantification.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. METAVIR (F0-F4): the global HCV-derived standard
2.1 Origin and criteria
METAVIR was developed in the 1990s by the French Meta-analysis of Histological Data in Viral Hepatitis consortium for chronic hepatitis C. The F0-F4 fibrosis staging was established in Bedossa 1994, PMID: 8020885, and the activity grading algorithm (A0-A3) was formalized in Bedossa & Poynard 1996, PMID: 8690394.
| Stage | Definition | Histology |
|---|---|---|
| F0 | No fibrosis | Normal liver, no portal tract expansion |
| F1 | Portal fibrosis without septa | Stellate enlargement of portal tracts |
| F2 | Few septa (bridging) | Portal expansion with occasional portal-portal septa |
| F3 | Many septa, no cirrhosis | Numerous bridges; partially preserved architecture |
| F4 | Cirrhosis | Regenerative nodules with complete fibrotic encasement |
Necroinflammatory activity is scored A0-A3 based on portal inflammation plus piecemeal necrosis (interface hepatitis).
2.2 Regulatory role
The HCV direct-acting antiviral (DAA) era cemented METAVIR (and its 5-stage Kleiner analog for MASH) as the common language regulators recognize. Most MASH Phase 2b/3 trials use "≥1 stage fibrosis improvement with no NASH worsening" as a co-primary endpoint, mirroring the METAVIR-style 5-stage scale.
[!NOTE] F2 as the "significant fibrosis" cutoff The AASLD 2023 MASLD Practice Guidance (Rinella ME et al.) classifies fibrosis using the terms "clinically significant fibrosis" (stage ≥ 2), "advanced fibrosis" (bridging fibrosis F3 or compensated cirrhosis F4), and "cirrhosis" (F4). Preclinical proof-of-concept models should induce at least F2-equivalent fibrosis to produce translatable data. See AASLD/EASL 2023-2024 guidance.
3. Ishak (0-6): built for cirrhosis sub-staging
3.1 Origin and criteria
The Ishak score was proposed in 1995 by NIH pathologist Kamal Ishak as a refinement of the Knodell HAI, introducing 7 stages for finer resolution PMID: 7560864.
| Stage | Definition |
|---|---|
| 0 | No fibrosis |
| 1 | Fibrous expansion of some portal areas, ± short septa |
| 2 | Fibrous expansion of most portal areas, ± short septa |
| 3 | Stage 2 + occasional portal-portal bridging |
| 4 | Marked bridging (portal-portal or portal-central) |
| 5 | Marked bridging + occasional nodules (incomplete cirrhosis) |
| 6 | Probable or definite cirrhosis |
3.2 Where Ishak wins
The headline feature is splitting METAVIR F4 into Ishak 5 (incomplete / developing cirrhosis) and Ishak 6 (established cirrhosis). This matters in three scenarios:
- Fibrosis regression detection. After long-term antiviral therapy or MASH drug exposure, Ishak can capture transitions like 6 → 5 → 4. Autoimmune hepatitis regression studies report higher sensitivity for Ishak than METAVIR.
- Patient stratification within cirrhosis. Separates the pre-decompensation zone histologically.
- Long-term cohorts. HCV post-SVR follow-up and PBC natural history studies lean on Ishak's granularity.
3.3 Convertibility with METAVIR
Comparative studies (Ishak vs METAVIR review, PMC4089240) propose an approximate mapping:
| METAVIR | Ishak (approx.) |
|---|---|
| F0 | 0 |
| F1 | 1–2 |
| F2 | 3 |
| F3 | 4 |
| F4 | 5–6 |
Note this is approximate — the F3/F4 boundary (Ishak 4 vs 5) is the most interpreter-dependent. Meta-analyses mixing both scores should explicitly justify the conversion.
4. Kleiner / Brunt (NASH CRN) for MASH
MASH (formerly NASH) trials use neither METAVIR nor Ishak as the primary system. The field adopted the NASH Clinical Research Network scoring by Kleiner/Brunt in 2005 PMID: 15915461.
4.1 Fibrosis stage (F0-F4, with F1 subdivided)
| Stage | Definition |
|---|---|
| F0 | No fibrosis |
| F1a | Mild zone 3 perisinusoidal fibrosis (requires trichrome) |
| F1b | Moderate zone 3 perisinusoidal fibrosis |
| F1c | Portal fibrosis only (no perisinusoidal) |
| F2 | Zone 3 perisinusoidal + portal/periportal |
| F3 | Bridging fibrosis |
| F4 | Cirrhosis |
4.2 NAFLD Activity Score (NAS, 0-8)
Steatosis (0-3) + Lobular inflammation (0-3) + Ballooning (0-2). Most MASH Phase 2/3 trials use dual co-primary endpoints: "≥2-point NAS improvement without fibrosis worsening" and "≥1-stage fibrosis improvement without NASH worsening" (e.g., resmetirom's MAESTRO-NASH).
[!TIP] Preclinical bridge: To translate fibrosis data from MASH animal models (AMLN/GAN diet, CCl4, TAA) into clinical language, combine Kleiner staging with hydroxyproline and Sirius Red %CPA.
5. Decision tree for drug developers
Q1. Indication?
├── HCV / HBV → METAVIR (default) or Ishak (if regression granularity needed)
├── MASH / MASLD → Kleiner/Brunt (NASH CRN)
├── PBC / AIH → Ishak (fine-grained regression)
└── Preclinical organ models → Kleiner or organ-specific (Ashcroft, etc.)
Q2. Endpoint granularity?
├── Primary endpoint (POC) → METAVIR or Kleiner (5 stages, regulator-familiar)
├── Long-term regression / cirrhosis stratification → Ishak (7 stages)
└── Complement with quantification → + hydroxyproline / Sirius Red %Area
Q3. Inter-observer variability (κ)?
├── Central pathology reading → ≥2 blinded readers
├── AI augmentation → HALO/QuPath DIA for %CPA
└── Multi-site harmonization → unified score + training slide set
6. Common interpretation pitfalls
6.1 "F2" is not always the same F2
METAVIR F2 and Kleiner F2 are similar but not identical. Kleiner F2 requires both perisinusoidal and portal/periportal fibrosis, reflecting the zone 3 onset characteristic of MASH. Always check which system a paper uses before comparing.
6.2 Sampling error
A needle biopsy captures roughly 1/50,000 of the liver, and Bedossa and colleagues have repeatedly shown 1–2 stage disagreement between adjacent cores. Central reading and multi-slice evaluation are non-negotiable in regulatory Phase 2/3.
6.3 F4 does not mean "end stage"
Compensated METAVIR F4 / Ishak 6 patients are routinely enrolled in MASH therapeutic trials (e.g., resmetirom MAESTRO-NASH OUTCOMES [NCT05500222], a dedicated Phase 3 outcomes study in compensated NASH cirrhosis; lanifibranor NATiV3 exploratory cohort, which spans F1-F4 with ~75 compensated cirrhotic patients alongside the F2-F3 main cohort). Do not exclude patients on histological stage alone.
6.4 Non-invasive markers: complement, not replacement
ELF score, PRO-C3, FibroScan (VCTE), and MRE correlate with histological stage but complement rather than replace biopsy. FDA accepts non-invasives to rule out significant fibrosis (F2+), but histology is still typically required for treatment-effect adjudication.
7. Preclinical and translational implementation
In non-liver organs, field-specific scores apply rather than METAVIR/Ishak:
- Pulmonary fibrosis: Modified Ashcroft Score (0-8) — the bleomycin model standard.
- Renal fibrosis: tubulointerstitial fibrosis %area plus semi-quantitative grading in UUO/IRI models.
- Skin fibrosis (SSc): Modified Rodnan Skin Score (MRSS, clinical) plus SSc model hydroxyproline.
For MASH preclinical studies destined for clinical translation, Kleiner staging is the de facto requirement on the pathology side. When contracting preclinical CROs, verify:
- Board-certified liver pathologist on the central reading panel
- ≥2-reader blinded workflow
- Historical ICC / κ values for inter-reader concordance
- Availability of digital image analysis (DIA) augmentation
CRO selection guidance: Fibrosis CRO Landscape 2026 and MASH 3D In Vitro CRO comparison.
8. Three takeaways
- METAVIR (F0-F4) is the 5-stage HCV-derived global standard and the regulator-facing common language; Kleiner/Brunt (NASH CRN) fills the same role for MASH.
- Ishak (0-6) offers 7-stage resolution, splitting cirrhosis into "incomplete" vs "established" — the preferred tool for regression studies and long-term AIH/PBC/post-SVR cohorts.
- Histological scores are semi-quantitative architectural grades. Pair them with hydroxyproline, Sirius Red %CPA, and AI pathology to produce regulator-grade evidence.
For the broader landscape, see the fibrosis assessment pillar and fibrosis quantification methods comparison 2026.
References
- The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15-20. PMID: 8020885 (original F0-F4 fibrosis staging)
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-293. PMID: 8690394 (A0-A3 activity grading algorithm)
- Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699. PMID: 7560864
- Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321. PMID: 15915461
- Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607. PMID: 17692984
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PMC: 10735173
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. Full text